Technology ID
TAB-4535

Advanced Human Cell Line Technology for RSV Replication Complex Production and Antiviral Drug Discovery

E-Numbers
E-235-2020-0
Lead Inventor
Le Nouen, Cyril (NIAID)
Co-Inventors
Marcotrigiano, Joseph (NIAID)
Buchholz, Ursula (NIAID)
Collins, Peter (NIAID)
Applications
Research Materials
Therapeutic Areas
Infectious Disease
Development Stages
Pre-Clinical (in vitro)
Research Products
Human Cell Lines
Lead IC
NIAID
ICs
NIAID

This technology includes the NeurEx® mobile application, a groundbreaking tool designed for neurologists to conduct and document neurological examinations efficiently. Deployed on iPads, it integrates with a secure, cloud-based database, automating the computation of four key disability scales used in neuroimmunology. The app's robust design enables precise mapping of neurological deficits, blending spatial distribution with quantitative assessments. Its effectiveness is underscored by a study involving 865 neurological exams, where the app's computed scales matched the accuracy of multiple sclerosis-trained clinicians. Crucially, NeurEx® enhances the sensitivity and specificity in tracking disability progression, outperforming traditional scales like the EDSS. This makes it an invaluable asset not only in clinical settings but also in research and multicentric trials, offering a more economical and precise alternative to conventional documentation of neurological examinations.

Commercial Applications
The technology holds promise for facilitating detailed structural studies of the RSV replication mechanism, advancing antiviral drug development, and potentially applying similar methods to other significant negative-sense RNA viruses like measles and ebola.

Competitive Advantages
This technology uniquely enables the high-yield production and purification of the RSV replication complex in human cells, paving the way for groundbreaking antiviral drug discovery and structural analysis of the virus.
Licensing Contact: